Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Should l Buy XNCR?
Source: Newsfilter
Public Offering Announcement: Xencor, Inc. has priced its public offering of 6,635,112 shares of common stock at $18.00 per share and pre-funded warrants for 3,088,888 shares at $17.99 each, aiming to raise approximately $175 million before expenses, with the offering expected to close around September 12, 2024.
Use of Proceeds: The company plans to utilize the net proceeds from this offering for general corporate purposes, including research and development, capital expenditures, and working capital.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XNCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XNCR
Wall Street analysts forecast XNCR stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.870
Low
20.00
Averages
26.25
High
30.00
Current: 11.870
Low
20.00
Averages
26.25
High
30.00
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xencor Lowers Outlook After Royalty Dispute
- Stock Price Decline: Xencor (XNCR) shares fell approximately 8% on Thursday, primarily due to the company's lowered outlook following a royalty dispute with AstraZeneca's subsidiary Alexion Pharmaceuticals, indicating market concerns about future earnings.
- Royalty Revenue Adjustment: Xencor stated that Alexion has informed the company it will no longer owe additional royalties related to Ultomiris net sales in the U.S., although payments for sales outside the U.S. will continue, potentially leading to future revenue uncertainty.
- Cash Flow Forecast Downgrade: The company updated its year-end cash guidance, projecting cash, cash equivalents, and marketable debt securities to reach $380 million to $400 million by year-end, down from the previous estimate of $400 million to $430 million, reflecting a cautious outlook on future operations.
- Shortened Operating Runway: Xencor's revised operating runway forecast has also been shortened, now expected to last until mid-2028, down from prior guidance, indicating increased financial pressure on the company amid the royalty dispute.
See More
Xencor Lowers Revenue Outlook for Ultomiris Royalties
- Revenue Outlook Revision: Xencor Inc. announced a revision of its revenue outlook for royalties tied to Ultomiris, as Alexion Pharmaceuticals stated it does not owe additional royalties on Ultomiris sales, which will directly impact Xencor's future cash flow and profitability.
- Cash Flow Forecast Adjustment: Xencor lowered its 2026 cash outlook from $400 million–$430 million to $380 million–$400 million, although it still expects its cash runway to support operations into mid-2028, indicating some financial pressure on the company.
- Analyst Perspective: William Blair holds a slightly negative view on Xencor's outlook, yet anticipates that clinical trial updates in 2026 will serve as more impactful catalysts, thus reiterating an Outperform rating, reflecting cautious optimism about the company's long-term potential.
- Technical Analysis Signals: Xencor's stock is currently trading below its 20-day and 100-day simple moving averages, indicating short-term weakness; despite an 83% increase in share price over the past 12 months, the mixed signals from RSI and MACD suggest investors should proceed with caution.
See More
Xencor Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Xencor reported a Q4 GAAP EPS of -$0.09, surpassing expectations by $0.50, indicating resilience in profitability despite ongoing financial challenges.
- Significant Revenue Decline: The company’s revenue of $28.24 million represents a 46.5% year-over-year decrease, missing market expectations, which may impact investor confidence in a competitive biopharmaceutical landscape.
- Strong Cash Reserves: As of December 31, 2025, Xencor held $610.8 million in cash, cash equivalents, and marketable securities, down from $706.7 million in 2024, reflecting cautious financial management amid operational challenges.
- Optimistic Partnership Outlook: The late-stage trial success of the lymphoma therapy partnered with Incyte, along with its EU approval, suggests potential growth opportunities for Xencor in drug development and market expansion.
See More
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Approval of Minjuvi: The European Commission has approved Incyte's drug Minjuvi, in combination with lenalidomide and rituximab, as a late-line treatment for adults with relapsed or refractory follicular lymphoma.
Second Indication: This approval marks the second indication for Minjuvi in the EU, following its conditional approval for use in relapsed or refractory diffuse large B-cell lymphoma.
See More
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
- Patent Extension: Xencor has been granted U.S. Patent 12,492,253 covering its Xtend™ Fc domain, extending the patent term to December 2028, which is approximately three years longer than the previous patent, ensuring low-single digit royalty income from Ultomiris.
- Potential Revenue Growth: Based on consensus sales forecasts, Xencor anticipates receiving an additional $100 million to $120 million in royalties during the extended patent term, which will support funding for its internal pipeline as it advances in clinical development.
- Strategic Partnership: OMERS has acquired royalties due to Xencor on global Ultomiris sales starting in 2026, with potential annual revenues of up to $35 million, enhancing the company's financial stability as excess royalties revert to Xencor.
- Technological Advantage: Xencor's Xtend antibody half-life extension technology provides new therapeutic mechanisms for its XmAb medicines, driving innovation in cancer and autoimmune disease treatments, aligning with its long-term value creation strategy.
See More
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
See More
Xencor Lowers Outlook After Royalty Dispute
- Stock Price Decline: Xencor (XNCR) shares fell approximately 8% on Thursday, primarily due to the company's lowered outlook following a royalty dispute with AstraZeneca's subsidiary Alexion Pharmaceuticals, indicating market concerns about future earnings.
- Royalty Revenue Adjustment: Xencor stated that Alexion has informed the company it will no longer owe additional royalties related to Ultomiris net sales in the U.S., although payments for sales outside the U.S. will continue, potentially leading to future revenue uncertainty.
- Cash Flow Forecast Downgrade: The company updated its year-end cash guidance, projecting cash, cash equivalents, and marketable debt securities to reach $380 million to $400 million by year-end, down from the previous estimate of $400 million to $430 million, reflecting a cautious outlook on future operations.
- Shortened Operating Runway: Xencor's revised operating runway forecast has also been shortened, now expected to last until mid-2028, down from prior guidance, indicating increased financial pressure on the company amid the royalty dispute.
See More
Xencor Lowers Revenue Outlook for Ultomiris Royalties
- Revenue Outlook Revision: Xencor Inc. announced a revision of its revenue outlook for royalties tied to Ultomiris, as Alexion Pharmaceuticals stated it does not owe additional royalties on Ultomiris sales, which will directly impact Xencor's future cash flow and profitability.
- Cash Flow Forecast Adjustment: Xencor lowered its 2026 cash outlook from $400 million–$430 million to $380 million–$400 million, although it still expects its cash runway to support operations into mid-2028, indicating some financial pressure on the company.
- Analyst Perspective: William Blair holds a slightly negative view on Xencor's outlook, yet anticipates that clinical trial updates in 2026 will serve as more impactful catalysts, thus reiterating an Outperform rating, reflecting cautious optimism about the company's long-term potential.
- Technical Analysis Signals: Xencor's stock is currently trading below its 20-day and 100-day simple moving averages, indicating short-term weakness; despite an 83% increase in share price over the past 12 months, the mixed signals from RSI and MACD suggest investors should proceed with caution.
See More
Xencor Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Xencor reported a Q4 GAAP EPS of -$0.09, surpassing expectations by $0.50, indicating resilience in profitability despite ongoing financial challenges.
- Significant Revenue Decline: The company’s revenue of $28.24 million represents a 46.5% year-over-year decrease, missing market expectations, which may impact investor confidence in a competitive biopharmaceutical landscape.
- Strong Cash Reserves: As of December 31, 2025, Xencor held $610.8 million in cash, cash equivalents, and marketable securities, down from $706.7 million in 2024, reflecting cautious financial management amid operational challenges.
- Optimistic Partnership Outlook: The late-stage trial success of the lymphoma therapy partnered with Incyte, along with its EU approval, suggests potential growth opportunities for Xencor in drug development and market expansion.
See More
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Approval of Minjuvi: The European Commission has approved Incyte's drug Minjuvi, in combination with lenalidomide and rituximab, as a late-line treatment for adults with relapsed or refractory follicular lymphoma.
Second Indication: This approval marks the second indication for Minjuvi in the EU, following its conditional approval for use in relapsed or refractory diffuse large B-cell lymphoma.
See More
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
- Patent Extension: Xencor has been granted U.S. Patent 12,492,253 covering its Xtend™ Fc domain, extending the patent term to December 2028, which is approximately three years longer than the previous patent, ensuring low-single digit royalty income from Ultomiris.
- Potential Revenue Growth: Based on consensus sales forecasts, Xencor anticipates receiving an additional $100 million to $120 million in royalties during the extended patent term, which will support funding for its internal pipeline as it advances in clinical development.
- Strategic Partnership: OMERS has acquired royalties due to Xencor on global Ultomiris sales starting in 2026, with potential annual revenues of up to $35 million, enhancing the company's financial stability as excess royalties revert to Xencor.
- Technological Advantage: Xencor's Xtend antibody half-life extension technology provides new therapeutic mechanisms for its XmAb medicines, driving innovation in cancer and autoimmune disease treatments, aligning with its long-term value creation strategy.
See More
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
See More
